Market Research Report
Global Human Microbiome Therapeutics Market: Focus on Drugs, Pipeline Analysis, Funding Scenario, Therapeutic Application, 10 Countries Data, and Competitive Landscape - Analysis and Forecast, 2019-2029
|Published by||BIS Research Inc.||Product code||915114|
|Published||Content info||193 Pages
Delivery time: 1-2 business days
|Global Human Microbiome Therapeutics Market: Focus on Drugs, Pipeline Analysis, Funding Scenario, Therapeutic Application, 10 Countries Data, and Competitive Landscape - Analysis and Forecast, 2019-2029|
|Published: October 23, 2019||Content info: 193 Pages||
Global Human Microbiome Therapeutics Market to Grow at a CAGR of 33.00% from 2019-2029
Human Microbiome Therapeutics Industry Analysis by BIS Research projects the market to grow at a significant CAGR of 33.00% during the forecast period 2019-2029. The human microbiome therapeutics market generated $309.9 million revenue in 2018, in terms of value.
The human microbiome therapeutics growth has been primarily attributed to the major drivers in this market such as increasing prevalence and growing incidence of chronic diseases, growing investments and initiatives in the field of microbiome therapeutics, treatment options with minimal or no side effects, availability of private and government funding, and others. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include product launches, and increasing merger and acquisitions among the industry players. However, there are significant challenges which are restraining the market growth. These challenges include exorbitant cost is required for the clinical trials procedure and stringent regulatory guidelines for the product development and commercialization of the products.
"With the elucidation of its causative role in cardiometabolic disease and atherosclerosis, the human gut microbiome holds promises as a reservoir of novel potential therapeutic targets as well as novel therapeutic agents, paving a new and exciting avenue in cardiovascular drug discovery and other areas."
The human microbiome therapeutics market research provides a holistic view of global market in terms of various factors influencing it, including regulatory reforms, and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products for different therapeutic applications in human microbiome therapeutics. In addition, the study also includes exhaustive information on expected commercial launches of the product in the forecast period, perception on the new product launches, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segments, and company, as well as other vital information with respect to global human microbiome therapeutics market.
The human microbiome therapeutics market is segmented into three categories, namely, product (by Phases), by disease, and by region.
The product segment includes the segmentation on the basis of different phases of clinical trials, and the disease segment includes, gastrointestinal and infectious diseases, oncology and autoimmune diseases, skin diseases, and neurological diseases.
The region segment is further segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World.
The key manufacturers who have been contributing significantly to the human microbiome therapeutics market include 4D Pharma plc, Immuron Limited, Sanofi SA., Seres Therapeutics Inc., Synthetic Biologics, Taisho Pharmaceutical, Ritter Pharmaceuticals, AOBiome, Finch Therapeutics, Rebiotix, Inc. (Subsidiary of Ferring Pharmaceutical), Maat Pharma, Ox Thera, Quorum Innovations, Vedanta Biosciences, Whole Biome, and Naked Biome among others.